sponsored
PatientsVille.com Logo

PatientsVille

Laxative Medical Research Studies

Up-to-date List of Laxative Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Laxative Medical Research Studies

Rank Status Study
1 Recruiting A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
Condition: Opioid Induced Constipation
Intervention: Drug: Laxative
Outcome Measures: Change from baseline in soft complete bowel movements;   Change from baseline (Visit 2 to 8 (Day 1 to 28)) in SCBM - Non Straining;   Additional laxative use (including enema) in addition to SLT (First Line and Second Line);   Additional procedures (e.g. manual bowel evacuation or surgical procedure) required in addition to SLT;   Bowel Function Index (change from baseline to each visit (Day 7, 14, 21 and 28));   Compliance with SLT/opioid therapy (premature discontinuation, SLT/opioid dose reduction or completely stopped SLT/opioid therapy).;   SLT/opioid-related AE and dropouts.;   The modified Subjective Opiate Withdrawal Scale at Day 7 and Day 28;   The Clinical Opiate Withdrawal Scale at Day 7 and Day 28;   Pain Intensity Scale - "Average Pain over last 24 Hours" at each visit (Day 7, 14, 21 and 28);   The 36-item Short Form Health Survey (SF-36 v2) at Day 7 and Day 28;   Clinical Global Impression (CGI) item 1 (severity) Day 28;   Clinical Global Impression (CGI) item 2-4 (condition, therapeutic effect, side effects) Day 7 amd 28;   The patient global impression of improvement (PGI-I) Day 28;   Healthcare resources used for OIC treatment during the study (between first dose and last dose during the four week treatment period).
2 Recruiting Improving Tolerability of Bowel Preparation Laxative for Colonoscopy
Conditions: Colonoscopy;   Bowel Preparation
Intervention: Other: Pattern of flavoring of bowel laxative
Outcome Measures: Overall patients' experience with the bowel preparation process with ratings from 1 (unbearable) to 10 (Pleasant);   Endoscopist ratings of the patient's bowel preparation quality using Aronchick scale
3 Unknown  Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome
Condition: Urge Syndrome
Intervention: Drug: Miralax
Outcome Measure:
4 Recruiting Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
Conditions: Pain;   Opioid Induced Constipation
Intervention:
Outcome Measure: Quality of Life
5 Recruiting MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery
Condition: Post Procedural Constipation
Interventions: Drug: MiraLax;   Drug: Placebo;   Drug: Rescue Laxative
Outcome Measures: Time to first postoperative bowel movement;   Other postoperative medication use;   Evaluation of symptoms and quality of life related to constipation;   Symptoms of Over-Effectiveness;   Evaluation of symptoms and quality of life related to constipation 6-weeks postoperatively
6 Recruiting Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease
Condition: Irritable Bowel Syndrome (IBS)
Interventions: Behavioral: CBT/ Hypnotherapy;   Drug: Routine Management
Outcome Measures: Functional Disability Inventory (FDI);   Pain Beliefs Questionnaire
7 Recruiting Longitudinal Study of Patients With Opioid-Induced Constipation
Condition: Opioid Induced Constipation in Patients Without Cancer and With Cancer
Intervention:
Outcome Measures: Rate of LIR among the OIC population;   Rate of inadequate response to first and second-line laxative treatment for OIC (1x LIR and 2x LIR).;   Baseline demographic and clinical characteristics of patients with OIC (prior health status, comorbidities, GI symptoms, and concomitant medications).;   Drug utilization and self-management of OIC at baseline and changes from baseline over the 24-week follow-up period.;   Healthcare resource utilization profiles pre- and post-baseline;   Cost of illness related to the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs.;   Baseline constipation-associated GI symptoms and changes from baseline over the 24-week follow-up period (PAC-SYM and additional symptom questions).;   Baseline health-related quality of life (PAC-QOL and EQ-5D) and changes from baseline over the 24-week follow-up period (PAC-QOL).;   Loss of productivity (WPAI-SHP score) at baseline and changes from baseline over the 24-week follow-up period.;   Persistence on opioid therapy at baseline and changes from baseline over the 24-week follow-up period;   Treatment satisfaction with laxative use at baseline and changes from baseline over the 24-week follow-up period, for all patients taking Laxatives.;   Physician-reported awareness of OIC and symptoms, and understanding of patient reported impact of OIC at baseline.
8 Not yet recruiting Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy
Condition: Patients Undergoing Screening or Surveillance Colonoscopy
Interventions: Drug: PEG+E;   Drug: PEG+Asc;   Drug: P+MC;   Drug: sulfate
Outcome Measures: Efficacy of bowel cleansing according to the Boston Bowel Preparation Score (BPPS);   Patient tolerability and satisfaction
9 Recruiting Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility
Condition: Laxative Compatibility
Intervention: Procedure: Compatibility
Outcome Measures: Valuation "very distressing";   Colon cleanness
10 Recruiting Maintenance Treatment for Children With Constipation
Condition: Constipation
Interventions: Drug: Polyethylene glycol 3350;   Other: Placebo
Outcome Measures: Treatment recovery;   Usage of laxative
11 Recruiting MRI and Microbiota Analysis in Constipation
Condition: Constipation
Interventions: Dietary Supplement: Ispaghula;   Dietary Supplement: Maltodextrin
Outcome Measures: Weighted Average Position Score of transit marker capsules as determined by MRI;   Weighted Average Position Score of 5 transit marker capsules, as determined by MRI;   Small Bowel Water Content (SBWC) in millilitres(mL) measured by MRI;   Small Bowel Water Content (SBWC) in millilitres measured by MRI;   Ascending Colon Water Content in millilitres measured by MRI;   Change from baseline in Ascending Colon Water Content in millilitre measured by MRI;   Change from before to after challenge meal in Ascending Colon Water Content before in millilitre measured by MRI;   Ascending Colon T1;   Descending Colon T1;   Ascending colon T2;   Descending Colon T2
12 Recruiting Pre-operative Bowel Preparation Prior to Minimally Invasive Sacral Colpopexy
Conditions: Pelvic Organ Prolapse;   Prolapse
Interventions: Other: Bowel preparation;   Other: No bowel preparation
Outcome Measures: PAC-SYM;   Surgeon perception of bowel preparation;   Return of normal bowel function;   Perioperative complications
13 Recruiting A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment
Condition: Chronic Severe Pain
Intervention: Drug: Targinact® (oxycodon/naloxon)
Outcome Measures: Assess the efficacy of Targinact® treatment;   • To assess pain (NRS) during Targinact® treatment compared to previous analgesic treatment (by physician);   To assess constipation (BFI) during Targinact® treatment compared to previous analgesic treatment (by physician);   To assess laxative use during Targinact® treatment compared to previous analgesic treatment (by physician);   To assess the use of analgesic rescue medication during Targinact® treatment compared to previous analgesic treatment (by physician);   To evaluate the quality of life (EQ-5D questionnaire) during Targinact® treatment compared to previous analgesic treatment (by patient);   To assess safety of Targinact® treatment (by physician)
14 Recruiting A Double-blinded,Double-dummy Clinical Trial of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation
Conditions: Functional Constipation;   Gastrointestinal Disorders
Interventions: Drug: MZRW;   Drug: Senna;   Drug: placebo
Outcome Measures: the responder rate for CSBM during the treatment period;   the responder rate for CSBM during the follow-up period;   Individual assessment of constipation and related symptoms;   the changes of colonic transit time;   Global symptom assessment;   Success of blinding;   safety profiles
15 Recruiting Colonoscopy Preparation Optimization for INpatients- COIN Study
Conditions: Endoscopy;   Bowel Preparation Solutions
Interventions: Drug: Bisacodyl 10mg;   Drug: Polyethelene Glycol;   Drug: Picosulfate sodium
Outcome Measures: Ottawa Bowel Prep Score;   Procedures Cancelled or repeated due to inadequate bowel preparation;   Individual Components of Ottawa Bowel Prep Score;   Adverse Effects;   Tolerability of the preparation
16 Recruiting Preparation Prior to Colonoscopy in Children
Condition: Inflammatory Bowel Diseases
Interventions: Drug: polyethylene glycol;   Drug: picosulphate
Outcome Measures: Clean colon/Ottowa scale;   Patient reported outcome measures
17 Recruiting Evaluation of Proposed EZ2go Complete Bowel Cleansing System
Conditions: Screening Colonoscopy;   Surveillance Colonoscopy;   Colonoscopy
Interventions: Other: Ez2go Complete;   Other: LoSo Prep
Outcome Measures: Measurement of Efficacy;   Evaluate the safety
18 Recruiting Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults
Condition: Colonoscopy
Intervention: Drug: Crystalline Lactulose
Outcome Measures: Cleanliness of the Colon During Colonoscopy;   Treatment Failures;   Patient Tolerability and Preference;   Colonic Hydrogen and Methane Gas Production;   Safety/Adverse Events
19 Recruiting Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy
Condition: Colonoscopy Preparation
Intervention: Drug: Bisacodyl and Lactulose
Outcome Measures: Efficacy of bisacodyl and lactulose as a preparation for colonoscopy.;   Safety of bisacodyl and lactulose as a bowel evacuant;   Tolerability of and preference for bisacodyl and lactulose as a bowel evacuant
20 Unknown  Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)
Condition: Acute Kidney Failure
Intervention:
Outcome Measure: NGAL

These studies may lead to new treatments and are adding insight into Laxative etiology and treatment.

A major focus of Laxative research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Laxative